Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1300 of 2051 entries
View as:

Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)

Phase: N/A Priority: Normal
NCT ID: NCT00535496 Org: User:
Start: 09/30/07 End: 02/29/08 Due: 02/28/09

Tolerability and Efficacy of Ibuprofen 800 mg in a Walking Model of Osteoarthritis Pain (0000-057)

Phase: N/A Priority: Normal
NCT ID: NCT00565084 Org: User:
Start: 03/31/07 End: 12/31/07 Due: 12/31/08

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

Phase: N/A Priority: Normal
NCT ID: NCT03486834 Org: User:
Start: 04/30/18 End: 06/30/21 Due: 06/30/22

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

Phase: N/A Priority: Normal
NCT ID: NCT06592339 Org: User:
Start: 10/25/22 End: 12/29/22 Due: 12/29/23

A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)

Phase: N/A Priority: Normal
NCT ID: NCT01558674 Org: User:
Start: 05/23/14 End: 12/17/14 Due: 12/17/15

Incidence of Incomplete Postoperative Neuromuscular Recovery From Anesthesia (P07535)(Completed)

Phase: N/A Priority: Normal
NCT ID: NCT01181349 Org: User:
Start: 07/31/10 End: 11/30/10 Due: 11/30/11

A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients

Phase: N/A Priority: Normal
NCT ID: NCT00002354 Org: User:
Start: - End: - Due: -

Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)

Phase: N/A Priority: Normal
NCT ID: NCT00106704 Org: User:
Start: 03/31/05 End: 01/31/07 Due: 01/31/08

Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)

Phase: N/A Priority: Normal
NCT ID: NCT00211601 Org: User:
Start: 08/31/04 End: 12/31/05 Due: 12/31/06

Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)

Phase: N/A Priority: Normal
NCT ID: NCT01544582 Org: User:
Start: 05/31/12 End: 07/31/15 Due: 07/31/16

Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00099450 Org: User:
Start: 12/31/04 End: 03/31/05 Due: 03/31/06

A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution

Phase: N/A Priority: Normal
NCT ID: NCT00680108 Org: User:
Start: 09/30/99 End: 05/31/00 Due: 05/31/01

A Study to Assess the Effect of Single and Multiple Doses Org 50081 and a Single Dose of Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers. (P05794) (COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00798395 Org: User:
Start: 10/31/07 End: 09/30/08 Due: 09/30/09

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Phase: N/A Priority: Normal
NCT ID: NCT03615482 Org: User:
Start: 09/14/18 End: 06/24/19 Due: 06/24/20

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Phase: N/A Priority: Normal
NCT ID: NCT02492763 Org: User:
Start: 07/27/15 End: 04/18/17 Due: 04/18/18

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Phase: N/A Priority: Normal
NCT ID: NCT01656408 Org: User:
Start: 08/01/12 End: 05/23/13 Due: 05/23/14

Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

Phase: N/A Priority: Normal
NCT ID: NCT00551018 Org: User:
Start: 12/31/07 End: 10/31/10 Due: 10/31/11

A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)

Phase: N/A Priority: Normal
NCT ID: NCT02059161 Org: User:
Start: 10/17/13 End: 11/12/15 Due: 11/12/16

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT05899049 Org: User:
Start: 07/27/22 End: 12/01/26 Due: 12/01/27

Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)

Phase: N/A Priority: Normal
NCT ID: NCT02403674 Org: User:
Start: 06/05/15 End: 09/07/23 Due: 09/07/24

A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00379964 Org: User:
Start: 06/30/05 End: 05/31/06 Due: 05/31/07

A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)

Phase: N/A Priority: Normal
NCT ID: NCT01018823 Org: User:
Start: 12/14/09 End: 03/18/10 Due: 03/18/11

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)

Phase: N/A Priority: Normal
NCT ID: NCT03293485 Org: User:
Start: 10/04/17 End: 09/14/18 Due: 09/14/19

A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)

Phase: N/A Priority: Normal
NCT ID: NCT01593735 Org: User:
Start: 05/31/12 End: 02/28/13 Due: 02/28/14

Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)

Phase: N/A Priority: Normal
NCT ID: NCT00988728 Org: User:
Start: 02/28/11 End: 07/31/12 Due: 07/31/13